




## Supplemental Figures and Figure Legends



**Supplemental Figure S1. IDO-activated Tregs prevent clonal expansion and pathology caused by allo-reactive T cells.** **A.** Sorted Tregs from CpG-treated and control ODN-treated donors were mixed with H-2K<sup>b</sup>-specific BM3 T cells and co-transferred into H-2K<sup>b</sup>-expressing CBK or CBA (antigen-negative) recipients. After 96 hours spleens were subjected to flow cytometric (**B**) and immunohistologic (**C**, **D**) analyses to detect donor BM3 cells (using Ti98 anti-clonotypic mAb). **B.** Data show absolute numbers of BM3 T cells present in spleen (mean of 2/group). Images (original magnifications x200) show spleen sections from mice receiving BM3 T cells, and Tregs from ODN-treated (**C**) and CpG-treated (**D**) donors.



**Supplementary Figure 2. Effect of CpG treatment on expression of CD80/86 and PD-L1/2 by splenic DCs.** B6 mice were treated with CpGs for 24 hours (100 $\mu$ g, i/v) and gated CD11c<sup>+</sup>B220<sup>+</sup> and CD11c<sup>+</sup>B220<sup>neg</sup> cells containing pDCs and mDCs respectively (dot plot), were analyzed to detect expression of CD80/86 and PD-L1/2 as indicated in the histograms (thick lines). DCs from untreated mice analyzed in parallel (thin lines) shown on each histogram revealed that levels of CD80 and PD-L2 were unaffected by CpG treatment, and levels of CD86 and PD-L1 expressed by DCs increased slightly following CpG treatment.



**Supplementary Figure 3. CpG treatment induces IDO-dependent maintenance of Foxp3 expression and inhibition of IL-17 expression by splenic CD4<sup>+</sup>CD25<sup>+</sup> Tregs.** B6 and IDO1-KO mice were treated with CpGs for 24 hours (100μg, i/v) and splenocytes were analyzed by flow cytometry to detect CD4<sup>+</sup>CD25<sup>+</sup> cells and analyze IL-17 and Foxp3 expression by gated CD4<sup>+</sup>CD25<sup>+</sup> cells as indicated. Proportions of CD4<sup>+</sup>CD25<sup>+</sup> cells amongst total CD4<sup>+</sup> T cells were within the range 8-9% for all samples, and >90% of gated CD4<sup>+</sup>CD25<sup>+</sup> cells expressed Foxp3, except when CD4<sup>+</sup>CD25<sup>+</sup> cells originated from CpG-treated IDO1-KO mice (lower right); in these samples >95% of CD4<sup>+</sup>CD25<sup>+</sup> cells did not express Foxp3.